National and Kapodistrian University of Athens
Πρωτεωμική ανάλυση των μεταβολών που επάγονται από τον NF-κB σε ανθρώπινα λεμφώματα
Abstract
dc:descriptionThe aim of the present study was to investigate the molecular mechanisms leading to the activation of the transcription factor NF-κB (Nuclear Factor κB) during the transformation of B-lymphocytes by Epstein Barr Virus (EBV). EBV is a human herpes virus that mainly infects B cells and is the causative agent of diverse lymphoma types , such as Burkitt’s lymphoma (BL). The precise role of the virus in the development of these diseases remains unclear, although it is known that EBV can transform resting B-lymphocytes into lymphoblastoid cell lines (LCLs). LMP-1 is an oncogenic viral protein that is necessary for the transformation of B-lymphocytes. This transformation depends upon the activation of NF-κB pathways, since inhibition of NF-κΒ leads the transformed B-lymphocytes to apoptosis. LMP-1 resembles a constitutively active CD40 receptor and transmits sustained proliferation and survival signals in B cells through signalling pathways, such as the canonical and non-canonical NF-κΒ pathways.NF-κΒ proteins are found in the cytoplasm where they are bound with inhibitor proteins also known as Inhibitors of NF-κΒ (IκΒ proteins). Different stimuli can cause the IκΒ proteins to be phosphorylated, ubiquitinated and finally degraded by the proteasome. Subsequently, NF-κΒ gets released and translocates into the nucleus where it binds on distinct promoter DNA sequences thus regulating the transcription of genes, such as cytokines, chomokines (IL-1α, IFNγ), immunoreceptors (molecules of the Major Histocompatibility Complex I-MHC-I), adhesion molecules (ICAM, VCAM), transcription factors (Α20 and IRF1), growth factors, enzymes, cell cycle regulators (cyclin D1), anti-apoptotic proteins (BCL-XL) and inhibitors of apoptosis (c-IAP1, c-IAP2, XIAP).The experimental approach used in the present study was the proteomic analysis of human B-lymphocytes cell lines from Burkitt lymphoma in the presence or absence of EBV (cell lines BL41/B95.8 and BL41) respectively, so that alterations induced by EBV could be defined in the protein level. These alterations could potentially be used as targets for prognostic or therapeutic purposes in human lymphomas. For the proteomic analysis and the comparison of expressed proteins between these two cell lines, two-dimensional electrophoresis was used. In order to reduce sample complexity and increase the number of proteins separated and identified, we employed both sub-cellular fractionation of the cells in order to enrich cytoplasmic and nuclear fractions, as well as narrow-range isoelectric focusing (IEF) gels, in addition to whole cell lysates and broad range IEF. Proteins differentially stained with silver nitrate were excised and digested with trypsin. Nano-high performance liquid chromatography (nano-HPLC) was used for the separation of tryptic peptides. Eluting peptides were introduced online into an LCQ Deca ion-trap mass spectrometer equipped with a nano-electrospray source. The MS raw file was searched using the SEQUEST algorithm against a merged and indexed IPI human (3.55) and EBV1/EBV2 protein database. Finally, for each identified protein the predicted or published molecular weight was checked against the one observed on the gels. Additionally the differentially proteins found were grouped according to their molecular function (Gene-Ontology).Using the two-dimensional electrophoresis technique (2DE) and protein identification by mass spectrometry, a number of proteins was found to be upregulated or downregulated in the EBV (+) cell line (BL41/B95.8). These proteomic alterations could be due to posttranscriptional mechanisms, posttranslational modifications or intracellular translocations.Confirming the validity of our experimental approach, several proteins, previously known to be regulated by EBV, were also found in our study and thus may be implicated in the development of lymphomas. Among them were vimentin, annexin VI, LDH-A, Interferon-induced GTP-binding protein Mx1, phosphoglycerate kinase 1 (PGK1), PI-9 or serpin B9, UCHL1 (ubiquitin carboxyl-terminal hydrolase isozyme L1), CDK4, the La antigen (Lupus La protein), 14-3-3 epsilon, actin and stathmin-1. Although generally there was concordance between our results and those of previous studies, some exceptions were seen, such as endoplasmin, which was found downregulated in our study but upregulated elsewhere and D-3-phosphoglycerate dehydrogenase, for which the opposite was true. Recently two studies were published identifying proteins or protein families, commonly found in many comparative proteomic studies irrespectively of the in vivo or in vitro conditions, the cells, the tissues or the experimental goal used and whose significance is therefore questionable. Some examples of these proteins that were also found in our study are: fructose biphosphate aldolase A, peroxiredoxin-6, alpha-enolase and gamma-enolase. However, some of the established targets of EBV infection mentioned above also belong to this list of generally detected proteins, e.g. vimentin, annexin VI, ezrin and stathmin-1. We therefore cannot exclude a role for a few additional such proteins with functions that may implicate them indirectly in EBV transformation. Additional proteins identified in our screen appear to play a role in growth regulation and cancer formation, while some are involved in actin regulation and the cytoskeleton or metabolic processes. They include septin-11, SET protein, Ran/TC4, ribose-5-phosphate isomerase, glucose-6-phosphate isomerase, Ly-GDI and deoxycytidine kinase.We noticed with interest in our screen that among the novel proteins found to be downregulated in the EBV (+) cell line were three members (COMMD2, -3 and –9) of a recently identified family, defined by the presence of a conserved motif called the COMM (Copper Metabolism gene MURR1) domain that contains conserved residues of tryptophan and proline, is rich in leucine residues and is implicated in protein-protein interactions. The family is evolutionarily conserved and consists of 10 members in vertebrates. The first member that was best characterised from this family is the protein COMMD1 (or Murr1), which is implicated in many diverse signaling pathways. It was first implicated in copper metabolism, facilitating copper excretion from the liver. It has also been shown to interact with different molecules such as ARF, GCN5 and HIF-1, probably promoting the ubiquitination and degradation of the latter. Similarly, it regulates NF-B by associating in the nucleus with E3 ubiquitin ligase, thus stabilizing the binding between SOCS1 and the amino-terminus of RelA, resulting in ubiquitination of NF-B. The other members of the family are less well characterized, however, they all seem to share the ability to interact with NF-B subunits and, by implication, affect their ubiquitination. In particular, COMMD3 and 9 have been found to bind and regulate RelB and p105, while COMMD2 can associate with a broad range of NF-B subunits.There is not much information available about the COMMD proteins found to be downregulated (COMMD2, -3 and –9) in the EBV positive cell line (BL41/B95.8) in our proteomic study. Antibodies are available against COMMD3 and COMMD9, but in our hands only the latter could recognize a specific band upon western-blotting. COMMD9 has one COMM domain and is expressed as two isoforms. The proteomic result of the differential expression of COMMD9 in the EBV (+) cell line was verified with Western analysis both in one-dimensional and two-dimensional gels. The differential expression of the two isoforms of COMMD9 was also verified in the transcriptional level using techniques such as RT-PCR and real time PCR (qPCR). In order to investigate whether this result is specific to the cell lines used, we also employed IB4, a lymphoblastoid cell line that contains four to five copies of viral DNA. As a control, we used B-lymphocytes from healthy individuals and it was found that COMMD9 protein levels were also reduced in this cell line. Similar experiments were conducted using an antibody against COMMD1, the protein that is best characterised from the COMMD family, whose levels do not seem to differ between EBV (+) and EBV (-) cell lines. Apart from IB4 LCL, another EBV (+) BL cell line was used, BL31/B95.8. The expression levels (protein and mRNA) of COMMD1 and COMMD9 were similar to those in the BL41/B95.8 cell line. Unfortunately the EBV (-) counterpart of the BL31/B95.8 cell line could not be tested because its culture was problematic.Since the available information concerning COMMD9 is very little, localization experiments were conducted from which it seems that COMMD9 is mainly located in the cytoplasm. In experiments with the protein synthesis inhibitor (Cycliheximide, CHX), COMMD9 appeared to be a very stable protein, at least for the cell lines used in this study. Furthermore, COMMD9 levels were not affected by the proteasome inhibitor MG132. Finally the effect of the NF-κΒ inhibitor BAY11-7082 was tested on the expression of COMMD9 at the protein and transcriptional level but again, expression levels of COMMD9 did not change. We were intrigued to see three members of this family as down-regulated in response to EBV infection. It is known that with 2DE and silver staining only a small portion of a mammalian proteome can be separated and detected. We therefore reckoned that additional members of the COMMD family may also be affected, but escaped detection in our proteomic screen. We therefore investigated the entire family at the mRNA level, using RT-PCR and real-time, qPCR between the cell lines BL41 and BL41/B95.8. Our findings suggest that at least seven members, COMMD2,3,4,7,8,9 and 10 are down-regulated by EBV infection, while COMMD1 and 6 are unaffected (COMMD5 was shown to be reduced with RT-PCR, but not with qPCR). Another possible way of COMMDs dowregulation in the EBV (+) cell lines is via the viral miRNAs that are expressed in the EBV (+) positive cell line. EBV is the first virus found to code for miRNAs. Till today there are almost 30 miRNAs found to be expressed by EBV. Apart from the viral miRNAs, the miRNAs of the host can also affect protein expression . This is why we used a bioinformatic model in order to predict which viral and cellular miRNAs can potently target COMMD proteins. Some COMMD proteins were found to be targets of viral miRNAs, while cellular miRNAs may target COMMD proteins as well.The experimental confirmation of the above was not applicable, since the cell lines used in the present study cannot be easily transfected. This limitation did not enable the conduction of other experimental procedures, such as the use of siRNA technology for silencing COMMD proteins in BL B-lymphocytes. The siRNA could have also been applied for NF-κΒ to investigate the outcome of this inhibition on COMMD expression . Due to this difficulty we used instead the NF-κB inhibitor BAY11-7082, which is a widely used but not very robust inhibitor. Our finding that three out of ten proteins were downregulated in our proteomic analysis and seven out of ten were downregulated at the mRNA level in the EBV (+) cell line, suggests a possible functional role for this regulation in oncogenic signaling by EBV in B-lymphocyte transformation. EBV exerts its transforming potential through the activation of NF-B pathways. On the other hand, the proposed role of COMMD proteins is negative regulation of NF-B function, mediating ubiquitination and degradation of this transcription factor. Thus, it is reasonable to suggest that by down-regulating COMMD proteins, the virus is further enhancing its effect on NF-B activation, by attenuating its degradation. It remains to be investigated how EBV reduces COMMD expression levels and how important this regulatory mechanism is for the development of Burkitt’s lymphoma and other EBV-associated diseases.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkiafi, Zacharati
- Γκιάφη, Ζαχαράτη
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29813